AVNR News Alert Avanir Pharmaceuticals Inc (AVNR) 13.41 11/05/2014

New Post Public Reply Private Reply Replies (0) Message Board

Nov 5, 2014 at 6:01 AM

Avanir Pharmaceuticals Inc (AVNR) 13.41 $AVNR

Will Avanir Pharmaceuticals (AVNR) Stock React Today to This Analyst Action?
at The Street - Tue Nov 04, 7:52AM CST
Deutsche Bank initiated coverage of Avanir Pharmaceuticals (AVNR) with a 'buy' rating and a price target of $17.
AVNR: 13.41 (+0.48)

Avanir Pharmaceuticals Announces Publication of Pivotal Phase III Results from AVP-825 Acute Migraine Study in the Journal "Headache"
PR Newswire - Thu Oct 30, 3:01PM CDT
Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced the publication of results from TARGET, a pivotal phase III study evaluating the efïcacy and safety of AVP-825 22mg in the January 2015 issue of Headache (Early access is now available). AVP-825 is an investigational drug-device combination product consisting of low-dose sumatriptan powder (22mg) delivered intranasally utilizing a novel Breath Powered(TM) delivery technology, for the acute treatment of migraine. A New Drug Application (NDA) for AVP-825 has been accepted and is currently under review by the U.S. Food and Drug Administration (FDA) with a Prescription Drug User Fee Act (PDUFA) goal date of November 26, 2014.
AVNR: 13.41 (+0.48)

Pharma Stocks Technical Data - Allergan, Zoetis, Actavis, Avanir Pharma, and Mallinckrodt
PR Newswire - Mon Oct 20, 7:40AM CDT
Investor-Edge has initiated coverage on the following equities: Allergan Inc. (NYSE: AGN), Zoetis Inc. (NYSE: ZTS), Actavis PLC (NYSE: ACT), Avanir Pharmaceuticals Inc. (NASDAQ: AVNR), and Mallinckrodt PLC (NYSE: MNK). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Friday, October 17, 2014, the NASDAQ Composite ended at 4,258.44, up 0.97%, the Dow Jones Industrial Average advanced 1.63%, to finish the day at 16,380.41, and the S&P 500 closed at 1,886.76, up 1.29%. The gains were broad based as all the sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 707.88, up 1.61%, with the index also advancing 0.29% in the previous three trading sessions. Register for your complimentary reports on these five stocks at:
MNK: 94.09 (+0.66), ZTS: 39.12 (+1.40), AGN: 195.12 (+1.98), AVNR: 13.41 (+0.48), ACT: 245.32 (-2.18)

Biotech Stock Mailbag: Small-Cap Rebound, Avanir, Ohr, CytoSorbents
at The Street - Fri Oct 17, 6:05AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care.
AVNR: 13.41 (+0.48), OHRP: 7.07 (-0.09), MNKD: 5.92 (unch), ARNA: 4.31 (+0.09)

Intra-Cellular Therapies Reveals Top-line Data on ITI-007 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 16, 4:50PM CDT
Intra-Cellular Therapies, Inc. (ITCI) announced top-line results from a phase I/II study (ITI-007-200) on the company's lead candidate, ITI-007.
MDVN: 103.83 (-1.57), AVNR: 13.41 (+0.48), LGND: 56.27 (-0.22), ITCI: 15.06 (-0.10)

Concert Pharmaceuticals Announces Positive CTP-354 Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 15, 5:04PM CDT
Concert Pharmaceuticals, Inc. (CNCE) recently announced encouraging data from a phase I study on CTP-354.
AVNR: 13.41 (+0.48), SHPG: 195.62 (-0.87), JAZZ: 168.48 (-1.85), CNCE: 14.62 (-0.18)

Avanir (AVNR) Presents Detailed Phase II Data on AVP-923 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 14, 4:30PM CDT
Avanir Pharmaceuticals, Inc. (AVNR) announced the presentation of phase II study results on AVP-923 for agitation in patients suffering from Alzheimer's disease.
AVNR: 13.41 (+0.48), UTHR: 124.81 (-5.61), PCRX: 89.98 (-1.28), HPTX: 24.32 (-0.39)

Avanir Pharmaceuticals Announces Presentation of AVP-923 Phase II Results in Agitation in Patients with Alzheimer's Disease at the American Neurological Association Meeting
PR Newswire - Mon Oct 13, 3:26PM CDT
Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that results from the Phase II study evaluating AVP-923 for the treatment of agitation in patients with Alzheimer's disease were presented at the 2014 American Neurological Association Meeting.
AVNR: 13.41 (+0.48)

Avanir Pharmaceuticals to Host Investor Briefing on October 15, 2014
PR Newswire - Wed Oct 08, 3:15PM CDT
Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) will host an Investor Relations Briefing on Wednesday, October 15, 2014 at 7:30 a.m. ET in New York City. At the meeting, members of the Avanir senior management team will provide a company update and discuss the results from the phase II clinical trial evaluating the safety and efficacy of AVP-923 for the treatment of agitation in patients with Alzheimer's disease.
AVNR: 13.41 (+0.48)

Avanir Pharmaceuticals Announces Data Presentations at the American Neurological Association's (ANA) 2014 Annual Meeting Including Results from the Phase II Trial for Treatment of Agitation in Patients with Alzheimer's Disease
PR Newswire - Wed Oct 08, 7:30AM CDT
Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that data from the phase II trial evaluating AVP-923 for the treatment of agitation in patients with Alzheimer's disease (AD) and the results of the phase IV PRISM II study evaluating NUEDEXTA® (dextromethorphan hydrobromide/quinidine sulfate) for the treatment of pseudobulbar affect (PBA) in patients with AD will be presented at the American Neurological Association's (ANA) Annual Meeting being held at the Marriott Waterfront Hotel in Baltimore, Maryland, October 12-14, 2014.
AVNR: 13.41 (+0.48)

Avanir Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
PR Newswire - Mon Sep 29, 8:15AM CDT
Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced the closing of its previously announced public offering of 20,930,000 shares of its common stock, including 2,730,000 shares sold pursuant to the underwriters' full exercise of their option to purchase additional shares, at a price to the public of $11.00 per share, before underwriting discounts. J.P. Morgan, Deutsche Bank Securities and BofA Merrill Lynch acted as joint book-running managers for the offering. Piper Jaffray and JMP Securities acted as co-managers for the offering.
AVNR: 13.41 (+0.48), JPM: 60.25 (-0.63), DB: 30.83 (-0.10)

Acquisitions, Senior Level Promotions, Public Offering, and Drug Approvals - Research Reports on Acorda, Alexion, Envision, Lilly and Avanir
PR Newswire - Mon Sep 29, 7:50AM CDT
Today, Analysts Review released its research reports regarding Acorda Therapeutics, Inc. (NASDAQ: ACOR), Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN), Envision Healthcare Holdings, Inc. (NYSE: EVHC), Eli Lilly and Company (NYSE: LLY) and Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6820-100free.
AVNR: 13.41 (+0.48), EVHC: 34.85 (-0.37), ALXN: 191.30 (+0.26), LLY: 67.17 (+0.63), ACOR: 34.78 (-0.40)

Avanir Pharma prices $200M stock offering
AP - Wed Sep 24, 10:06AM CDT
NEW YORK (AP) — Avanir Pharmaceuticals said Wednesday it priced a new stock offering worth about $200 million.
AVNR: 13.41 (+0.48)

How Will Public Offering Pricing Affect Avanir Pharmaceuticals (AVNR) Stock Today?
at The Street - Wed Sep 24, 9:10AM CDT
Shares of Avanir Pharmaceuticals (AVNR) were up in morning trading Wednesday after the company priced its public offering of common stock.
AVNR: 13.41 (+0.48)

Avanir Pharmaceuticals Announces Pricing of Public Offering of Common Stock
PR Newswire - Tue Sep 23, 9:00PM CDT
Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced the pricing of a public offering of 18,200,000 shares of its common stock in an underwritten public offering at a price to the public of $11.00 per share, before underwriting discounts. J.P. Morgan, Deutsche Bank Securities and BofA Merrill Lynch are acting as joint book-running managers for the offering. Piper Jaffray and JMP Securities are acting as co-managers for the offering. Avanir has granted the underwriters a 30-day option to purchase up to an additional 2,730,000 shares of its common stock in connection with the offering. All of the shares to be sold in the offering are being sold by Avanir. The offering is expected to close on or about September 29, 2014, subject to customary closing conditions.
AVNR: 13.41 (+0.48), JPM: 60.25 (-0.63), DB: 30.83 (-0.10)

Avanir Pharmaceuticals Announces Proposed Public Offering of Common Stock
PR Newswire - Mon Sep 22, 3:45PM CDT
Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that it is offering to sell $200 million of its common stock in an underwritten public offering. J.P. Morgan, Deutsche Bank Securities and BofA Merrill Lynch are acting as joint book-running managers for the offering. Avanir intends to grant the underwriters a 30-day option to purchase additional shares of its common stock. All of the shares to be sold in the offering are being sold by Avanir. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.
AVNR: 13.41 (+0.48), JPM: 60.25 (-0.63), DB: 30.83 (-0.10)

Nasdaq stocks posting largest percentage decreases
AP - Fri Sep 19, 12:33PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
GLAD: 9.08 (-0.11), AVNR: 13.41 (+0.48), UNXL: 4.82 (-0.03), BBSI: 23.76 (+0.85), RPRX: 6.50 (unch)

Weakness Seen in Avanir Pharmaceuticals (AVNR): Stock Falls 6.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Sep 19, 7:52AM CDT
Avanir Pharmaceuticals has been witnessing a flat trend in its consensus loss estimate for past 1 month and its share price has been declining for past few days
LCI: 56.25 (-1.27), ENDP: 68.67 (+0.17), AVNR: 13.41 (+0.48), HPTX: 24.32 (-0.39)

Merck KGaA Teams Up with Sutro for ADCs Targeting Cancer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 18, 6:00PM CDT
Merck KGaA's (MKGAF) signed a collaboration and license agreement with Sutro Biopharma to develop antibody drug conjugates (ADCs) targeting cancer cells.
LCI: 56.25 (-1.27), AVNR: 13.41 (+0.48), SGEN: 36.57 (-0.68)

Insider Trading Alert - RSG, HAL And AVNR Traded By Insiders
at The Street - Thu Sep 18, 9:30AM CDT
Stocks with insider trader activity include RSG, HAL and AVNR
AVNR: 13.41 (+0.48), HAL: 51.18 (-2.70), RSG: 38.23 (+0.16)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Webull Faces Class Action: Investor Impact Deep Dive

What's Going On with Webull? Ah, Webull Corporation, you're in the hot seat now. If you blinked on October 7th, you might have missed a monumental 19.09% cliff dive in Webull's stock, tumbling down to a humble $5.89. The roar wasn't just the market reacting; it was the sonic boom of a class action lawsuit on their heels, alleging some slick legal sledding with misleading...

Junior Golf Stars Shine at Notah Begay III Championship

Ever wonder where the golf stars of tomorrow get their start? Well, you might find a few of 'em teeing off at the Notah Begay III Junior Golf National Championship. This year, the spotlight is shining on the fairways of the Coushatta Resort in Louisiana. And let me tell you, the talent pool is something to behold. Young golfers from across the globe are swinging their way...

Marc Ryan Joins ABCS Insights as Chief Product Officer

Shaping the Future of Advertising Effectiveness In the ever-evolving ad measurement arena, where understanding what works can make or break a company, ABCS Insights has tossed a game-changing hat into the ring. They've just announced Marc Ryan as their new Chief Product Officer. Now, I’ve seen seasoned execs shuffle seats countless times, but this one’s...

ATTACK SHARK's X60: A New Era in Gaming Audio

Gaming Audio Gets a Power Boost with X60 We're diving headfirst into an era where gaming headsets promise more bells and whistles than ever before. This isn't just some random gadget plopped on the market. ATTACK SHARK's X60 Gaming Headset is strutting in, guns blazing, ready to take on the heavyweights in the competitive gaming world. It's not just about being another...

Cyclists and Trains: A New Chapter in Urban Travel

Rolling Without Engines: LA to SD Picture this: over 75 cyclists and their compact, foldable steeds embarking on a train journey from Los Angeles to the sun-drenched streets of San Diego. In an era where travel is often synonymous with congestion and pollution, this collaboration between Amtrak's Pacific Surfliner and Brompton Bicycle was like a breath of fresh sea air....

Tiny Fish Revolutionizes Vertebrate Gene Studies

From Small Fish to Big Discoveries: Meet Danionella cerebrum Who would've thought a diminutive fish with a see-through body would give a jolt to the study of vertebrate genomes? Thanks to Danionella cerebrum, researchers at the Whitehead Institute have created the very first complete whole-body single-cell atlas of an adult vertebrate. Forget the Wall Street clamor for a...

Service Pros Adds Windshield Repair to Lineup

Revving Up the Service Engine Alright, folks, buckle up because Service Pros Auto Glass, our local go-to for windshield replacements, is cranking up their game. They're stepping into the windshield repair arena across Florida and South Carolina, aiming to save you a buck and keep you safe behind the wheel. That's a double win if you ask me. A Closer Look at the Details...

Navigating Homeowner Deductibles: Balancing Costs

Understanding the Basics: Premiums and Deductibles Picture sorting through bills with a cup of lukewarm coffee, wondering if there’s a smarter way to handle homeowner insurance. Chuck Montgomery cuts through the fluff, talking turkey about balancing insurance dollars. One part of the game is deciding your deductible, the sum you fork over before insurance steps in...

Palmetto Publishing's M&A Guide Aims to Boost Home Services

Palmetto's New Release: Mergers & Acquisitions Focus Man, Palmetto Publishing just dropped a bombshell for home services aficionados with their latest M&A guide. Now, if you’re like me, swimming in stocks and always looking for that next big exit play, this one’s tailor-made for you. Mergers and acquisitions might not sound as flashy as the tech darlings or...

Jack Henry's Q1 2027 Deconversion Revenue Hits $17.9M

Jack Henry Surprises with Strong Deconversion Revenue You're probably thinking, deconversion revenue—what on earth is that? Imagine you're in the financial tech business and one of your bigwig clients decides to merge or get gobbled up by another institution. They move shop, and voila, you've got some unexpected money flowing in due to that exit. That's deconversion...